Antimicrobial

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the…

1 year ago

Immuron achieves record monthly Travelan® sales

Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales)MELBOURNE, Australia, Sept.…

1 year ago

Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Sept. 12, 2023 (GLOBE…

1 year ago

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago

Neil Lathangue Appointed President of DCS Global

DCS launches new service to save money and improve ESG performanceSupporting building owners, operators, facility and property managementToronto, Ontario--(Newsfile Corp.…

1 year ago

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023

• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership…

1 year ago

T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs

The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core ElementsLEXINGTON, Mass., Aug. 28, 2023 (GLOBE…

1 year ago

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

1 year ago

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

Sandoz completes acquisition of worldwide brand rights for Mycamine®(micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes,…

1 year ago